Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer [0.03%]
可切除型胰腺癌新辅助治疗的更新与展望
William Cobb,Daniel Rozefort,Chunghun Ji et al.
William Cobb et al.
Importance: Pancreatic adenocarcinoma (PDAC) is a disease process that carries high morbidity and mortality and is suspected to supplant colorectal cancer as the second leading cause of cancer-related death in the United ...
Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab [0.03%]
替西珠单抗治疗的多发性骨髓瘤患者静脉注射免疫球蛋白感染预防的研究
Michael Sheu,Sofia Molina Garcia,Meera Patel et al.
Michael Sheu et al.
Introduction: B-cell maturation antigen-targeting bispecific antibodies such as Teclistamab have been associated with increased risk of infections as compared with conventional treatment regimens. This study explored the ...
Impact of Abemaciclib-induced Serum Creatinine Elevation on Dose Adjustment of Concomitant Medications [0.03%]
阿贝西利致血清肌酐升高对合并用药剂量调整的影响
Kengo Umehara,Yoshitaka Saito,Shinya Takada et al.
Kengo Umehara et al.
Introduction: Abemaciclib (ABE) is a selective cyclin-dependent kinase 4/6 inhibitor widely used in breast cancer treatment. ABE inhibits renal tubular transporters such as organic cation transporter 2, multidrug and toxi...
From Radium to Radiosensitizers: A Centennial Reflection on Halberstaedter's Contributions to Oncology [0.03%]
从放射到增敏：庆祝哈伯斯坦达百年对肿瘤学的贡献
Saskia Hazout,Christoph Oehler,Daniel Rudolf Zwahlen et al.
Saskia Hazout et al.
This paper reviews a 1928 article by Prof. Ludwig Halberstaedter. He describes radiotherapy at the University Institute for Cancer Research, Charité Hospital in Berlin, Germany, marking its 25th anniversary, with added historical and scien...
Risk factors for lower adherence to epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer: A nationwide retrospective cohort study in Japan [0.03%]
日本全国性非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂低顺应性的危险因素：一项回顾性队列研究
Yasutaka Ihara,Shoichiro Yamamoto,Megumi Mizutani et al.
Yasutaka Ihara et al.
Introduction: The prognosis of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (EGFR-m-NSCLC) has improved with the introduction of oral EGFR- tyrosine kinase inhibitor (TKI). L...
Sex differences in cardiotoxicity of anaplastic lymphoma kinase inhibitors: An analysis of the FDA Adverse Event Reporting System [0.03%]
间变性淋巴瘤激酶抑制剂的心脏毒性性别差异：对美国食品药品监督管理局不良事件报告系统的分析
Hiroki Asano,Yoshihiro Noguchi,Rikuto Masuda et al.
Hiroki Asano et al.
Introduction: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have transformed the management of ALK-rearranged non-small-cell lung cancer (NSCLC), yet their cardiotoxicity profile remains incompletely ch...
Safety and Treatment Continuity of Switching Between CDK4/6 Inhibitors for Metastatic Breast Cancer Due to Adverse Events: An Exploratory Single-Center Study in Japan [0.03%]
由于不良事件而切换使用CDK4/6抑制剂的安全性和治疗连续性（针对转移性乳腺癌）：日本单中心研究的探索性结果
Makiko Go,Michio Kimura,Shiori Yamada et al.
Makiko Go et al.
Palbociclib and abemaciclib, CDK4/6 inhibitors with a shared primary mechanism of action, differ in their adverse effect profiles. We encountered several cases of switching between CDK4/6 inhibitors following treatment discontinuation owing...
Development and validation of the PREVES-HOR Questionnaire: a patient-reported measure of hormone-therapy-related quality of life in prostate-cancer patients undergoing androgen-deprivation therapy [0.03%]
前列腺癌患者接受雄激素剥夺治疗相关的生活质量的患者报告结局测量工具PREVES-HOR问卷的制订和验证
Giuseppe Di Lorenzo,Antonio Verde,Luca Scafuri et al.
Giuseppe Di Lorenzo et al.
Background: The burden of androgen-deprivation therapy (ADT) is only partially captured by legacy prostate-cancer questionnaires, which devote few items to hormonal sequelae. PREVES-HOR is a 29-item, distress-anchored ins...
Risk factors for the exacerbation of esophageal varices in patients receiving atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma [0.03%]
阿特朱单抗联合贝伐珠单抗治疗不可切除肝细胞癌患者食管曲张静脉加重的风险因素分析
Hitomi Takada,Leona Osawa,Yasuyuki Komiyama et al.
Hitomi Takada et al.
Introduction: Atezolizumab plus bevacizumab (AB) therapy is an effective systemic therapy for unresectable hepatocellular carcinoma (u-HCC). However, exacerbations of esophageal varices (EV) often occur, and EV management...
Differences in Safety Signal Detection Between Osimertinib and First- and Second-Generation EGFR-TKIs: A Pharmacovigilance Study Using a Spontaneous Reporting System [0.03%]
基于自发报告系统的埃克替尼药物警戒研究
Tomoya Sugimoto,Yoshihiro Noguchi,Rikuto Masuda et al.
Tomoya Sugimoto et al.
Aims: This study aimed to evaluate the trends in safety signal detection of osimertinib compared with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) through volcano plot analysis, using data...